
    
      1) Each dose group will be comprised of 8 participants (6 randomized to allopregnanolone; 2
      randomized to placebo) administered one dose of allopregnanolone or placebo once per week for
      12 weeks. A higher dose will be administered to the next group of participants when the lower
      dose is shown to be safe and tolerable. 2) Pharmacokinetic analyses will be conducted on
      blood samples taken from participants at the beginning and end of the trial. 3) The trial
      will assess safety including via MRI brain imaging.
    
  